Skip to main content
. 2018 Mar 5;128(4):1413–1428. doi: 10.1172/JCI98047

Figure 3. Induction of PD-L1 in NDV-treated and distant tumors.

Figure 3

(A) mRNA expression of PDL1 and PDL2 in the cultured NDV-infected tumor specimens (48 h) and NDV-infected whole blood (24 h) obtained from healthy donors and from patients with cancer. (B) Mouse treatment schema. Tumors were collected at 24 hours (early) or 6 days (late) after the first treatment. (C and D) Upregulation of PD-L1 on CD45+ and CD45– cells in treated tumors (C) and distant tumors (D) at 24 hours (early). Left: representative flow cytometry histograms; right: quantified PD-L1 MFI. (E and F) Upregulation of PD-L1 on CD45+ and CD45– cells in treated tumors (E) and distant tumors (F) on day 6 (late). Shown are representative flow cytometric histograms and quantification of PD-L1 MFI on CD45– cells and on the indicated leukocyte subsets. (G) Expression of PD-L1 in distant tumors on day 6. (H) MFI of PD-L1 expression in GFP– and GFP+ CD45+ cells isolated from the tumors treated with NDV expressing GFP 24 hours after infection. Scale bars: 500 μm and 50 μm (enlarged insets). (A) Each specimen represents an individual experiment. (B–H) Results are representative of 3 independent experiments with 3 to 5 animals per group, and data represent the mean ± SEM. Data were analyzed by a Wilcoxon matched-pairs, signed-rank test (A) and a Student’s t test for individual comparisons (C–F and H). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. MFI, median fluorescence intensity.